TP53 and breast cancer: In conclusion, based on the results from this study, we report that Sirt3, despite improving the mitochondrial function of MCF-7 breast cancer cells, reduces their response to E2, affects p53 by disruption of the ERα–p53 interaction, and inhibits clonogenic cell growth.